A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.

Authors: Renata Ferrarotto, John M. Kaczmar, David R. Spigel, Christine H. Chung, Dan Paul Zandberg, Irene Brana, Caroline Even, Kevin Joseph Harrington, Lisa F. Licitra, Bhumsuk Keam, Danny Rischin, Rita P. Dalal, David Raben, Rachel Salazar, Jeltje Schulten, Glenn J. Hanna

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6113

Source: Full article

---

Abstract

TPS6113